{
    "clinical_study": {
        "@rank": "99324", 
        "arm_group": [
            {
                "arm_group_label": "Etoricoxib", 
                "arm_group_type": "Experimental", 
                "description": "Etoricoxib 60 mg once daily"
            }, 
            {
                "arm_group_label": "matching placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "matching placebo once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The hypothesis is that Etoricoxib act as an adjuvant to SRP in alleviating periodontal\n      inflammation by:\n\n        1. improving clinical periodontal parameters and,\n\n        2. improving the salivary SOD levels."
        }, 
        "brief_title": "EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Cyclooxygenase Two Inhibitors", 
            "Etoricoxib", 
            "Periodontitis", 
            "Superoxide Dismutase", 
            "Saliva"
        ], 
        "condition_browse": {
            "mesh_term": "Periodontitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:Forty patients with chronic generalized periodontitis\n\n        -\n\n        Exclusion Criteria:with  system illnesses, allergies, pregnancy, history of any drug\n        intake and periodontal treatment in past 6 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149758", 
            "org_study_id": "sum2141"
        }, 
        "intervention": {
            "arm_group_label": [
                "Etoricoxib", 
                "matching placebo"
            ], 
            "intervention_name": "Etoricoxib", 
            "intervention_type": "Drug", 
            "other_name": [
                "Nucoxia", 
                "Arcoxia"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Superoxide Dismutase", 
                "Etoricoxib", 
                "Cyclooxygenase 2 Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Cyclooxygenase two inhibitors", 
            "Etoricoxib", 
            "Periodontitis", 
            "Superoxide dismutase", 
            "Saliva"
        ], 
        "lastchanged_date": "May 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kolhapur", 
                    "country": "India", 
                    "state": "Maharashtra", 
                    "zip": "416137"
                }, 
                "name": "Tatyasaheb kore Dental College And Research Centre"
            }
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).", 
        "overall_official": {
            "affiliation": "Tatyasaheb Kore Dental College And Research Centre", 
            "last_name": "Dr.Sumit S. Shetgar, BDS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "India: Indian Council of Medical Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "change from baseline in salivary SOD level", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149758"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tatyasaheb Kore Dental College", 
            "investigator_full_name": "Dr. Sumit Sharad Shetgar", 
            "investigator_title": "BDS (Post graduate student", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Tatyasaheb Kore Dental College", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tatyasaheb Kore Dental College", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}